New diagnostic guidelines aim to distinguish common memory disorder from Alzheimer’s

LATE-NC diagnostic criteria improve differentiation from Alzheimer’s, addressing challenges in memory-loss syndromes and guiding therapeutic interventions.

Clearmind Medicine Announces Exclusive, Long-Term Licensing Agreement with Leading Israeli Research Center | Psychedelic Invest

Tel Aviv, Israel / Vancouver, Canada, Feb. 01, 2024 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “company”), a

February 2, 2024

Xlife Sciences AG Announces the Intended Listing of VERAXA Biotech AG on the NASDAQ Stock Exchange in the 2025 Fiscal Year – Biotech Investments

Xlife Sciences AG / Key word(s): IPO/Market launch 16-Dec-2024 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer

December 17, 2024

Adaptimmune’s second T cell receptor cell therapy for rare sarcomas passes pivotal test

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

November 14, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.